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The immune response induced by immunization with HIV Env DNA and virus-like particle (VLP) vaccines was investigated.
Immunization with the HIV Env DNA vaccine induced a strong CD8 T cell response but relatively weak antibody response
against the HIV Env whereas immunization with VLPs induced higher levels of antibody responses but little CD8 T cell response.
Interestingly, immunization with a mixture the HIV Env DNA and VLP vaccines induced enhanced CD8 T cell and antibody
responses. Further, it was observed that the mixing of DNA and VLP vaccines during immunization is necessary for augmenting
induction of CD8 T cell responses and such augmentation of CD8 T cell responses was also observed by mixing the HIV Env DNA
vaccine with control VLPs. These results show that immunization with a mixture of DNA and VLP vaccines combines advantages
of both vaccine platforms for eliciting high levels of both antibody and CD8 T cell responses.
1.Introduction
Since the identiﬁcation of the human immunodeﬁciency
virus (HIV) as the causative agent of AIDS twenty-ﬁve
years ago, tremendous amount of eﬀort has been poured
into vaccine development. However, despite the signiﬁcant
progress that has been made over the last two decades,
an eﬃcacious AIDS vaccine strategy is still elusive. Earlier
clinical trials using HIV Env-based subunit vaccines failed
to show signiﬁcant protection against HIV infection or
disease progression [1–3]. Subsequent studies in nonhuman
primates showed that induction of a strong cellular immune
response against SIV and HIV antigens, particularly a strong
cytotoxic CD8 T cell response, was able to exert a successful
control of disease progression and AIDS development [4–7].
However, despite the promising results obtained in animal
studies, the results from a recent clinical trial of a T-cell-
based vaccine regimen dealt another setback to AIDS vaccine
development [8]. The disappointing outcomes from these
vaccine trials further reinforce the notion that an eﬀective
AIDS vaccine should be able to induce both strong antibody
and cytotoxic T cell responses against HIV [9–12].
A number of studies have shown that DNA vaccines
can eﬀectively induce both antibody and T cell responses
against their encoded antigens [13, 14]. DNA immunization
induces immune responses through both direct transfection
ofantigenpresentingcells(APCs)andcrossprimingofAPCs
[14, 15]a n do ﬀers several advantages over other vaccine
platforms. First, the direct in vivo expression of antigens by
DNAvaccinationrendersitmoreeﬀectiveinelicitingcellular
immune responses than protein-based vaccines, as in vivo
synthesized antigens are processed and presented through
both major histocompatibility complex I and II for inducing
both CD4 and CD8 T cell responses. Second, expression of
theantigensoveralongperiodoftimeafterDNAvaccination
may provide sustained stimulation of the immune system for2 Journal of Biomedicine and Biotechnology
inducing long lasting immune responses [16]. Third, DNA
vaccinescanbeappliedrepeatedlywithoutinducingimmune
responsesagainstthevectorincontrasttorecombinantviral-
vector-based vaccines.
Virus-like particles (VLPs) represent another attractive
concept for vaccine development [17–19]. VLPs share with
DNA vaccines the ability to be administered repeatedly to
vaccinated individuals. The nonreplicative nature of VLPs
and their lack of viral genomic RNA make them safe for
broad and repeated application. Since the assembly and
arrangement of viral glycoproteins in VLPs resemble intact
virions, they are likely to be more eﬀective in inducing
neutralizing antibodies as compared with soluble antigens.
Earlierstudieshaveshownthataviralglycoproteinpresented
in a highly repetitive form in virus particles is more potent in
inducing B cell response and antibody production than the
same antigen presented in a poorly organized form [20, 21].
Inseveralstudies,HIVVLPshavebeenshowntoinduceboth
neutralizing antibodies and CTL responses to HIV antigens
[22, 23].
While both the HIV DNA and VLP vaccines can induce
antibody as well as cytotoxic T cell responses [12, 24, 25],
DNA vaccines induce immune responses through direct in
vivo antigen synthesis whereas VLP vaccines directly present
viral glycoproteins on the surface of a particulate antigen.
As a result of their diﬀerent properties, immune responses
induced by these two vaccine platforms are likely to be
diﬀerent. In this study, we compared the immunogenicity of
HIV Env-DNA and VLP vaccines and investigated whether
a combination of these two vaccine platforms may comple-
ment each other when given as a mixture for inducing both
antibody and CD8 T cell responses.
2.MaterialsandMethods
2.1. Preparation of DNA and VLP Vaccines. The HIV 89.6
Env718Tr/Y710S DNA construct, designated as Env-DNA,
has been described in previous studies [26] For large-scale
preparation, the plasmids were ampliﬁed in E. coli DH5α
and puriﬁed with a Qiagen Endo-Free Megaprep kit. The
plasmids were then resuspended at 1μg/μl in sterile PBS and
stored at −80◦C until used for immunization. Construction
of recombinant baculoviruses expressing the SIV Gag (rBV-
Gag) and the HIV 89.6 Env protein (rBV-Env) has also
been described previously [27, 28]. SHIV 89.6 VLPs were
produced by coinfection of Sf9 insect cells with rBV-Gag and
rBV-Env at a multiplicity of 2 and 5, respectively. At 60 hours
post infection, medium from infected cells was collected and
clariﬁed of cell debris by centrifuge at 7,000rpm in a Sorvall
SS-34 rotor for 20 minutes. The VLPs in the supernatant
were concentrated by ultracentrifugation at 28,000rpm for
1 hour in a Beckman SW28 rotor, resuspended in PBS, and
further puriﬁed by centrifugation through a discontinuous
sucrose gradient (20%, 35%, and 50% layers) at 30,000rpm
for 1 hour in a Beckman SW41 rotor. The band that
containedVLPs(between35%and50%layers)wascollected,
concentrated, and then resuspended in PBS at a ﬁnal
concentration of 2μg/μl. The integrity of puriﬁed VLPs was
examined by electron microscopy and the presence of SIV
Gag and HIV 89.6 Env proteins in VLP preparations was
determined by western blot analysis as described previously
[28]. Protein concentration of the VLP preparation was
determined by a BCA protein assay (Pierce Biotechnology,
Rockford, IL) and the amount of HIV 89.6 Env proteins in
the VLP preparation were determined by a sandwich ELISA
using puriﬁed HIV 89.6gp120-Histag as standards. The VLP
preparation was stored in −80◦C until immunization and
the same VLP preparation was used in the immunization
experiments throughout this study. The SIV Gag only VLPs
were produced by infection of Sf9 cells with rBV-Gag at the
multiplicity of 2 and puriﬁed similarly as described above.
2.2. Immunization of Mice. Female BALB/c mice (H-2d)
6–8 weeks of age were purchased from Charles River
Laboratory. Mice were housed in the animal facility operated
by the Division of Animal Resources at Emory University.
All procedures were carried out following animal research
guidelines and approved by IACUC. For immunization with
DNA or VLP vaccines alone, groups of mice (six mice per
group) were immunized with 50μg DNA or VLPs dissolved
in 100μl PBS per mouse by intramuscular injection in
both side quadriceps with 50μl of the preparations at each
side. For immunization with a mixture of DNA and VLPs,
50μgD N Aa n d5 0 μg VLPs were mixed in 100μl PBS
prior to immunization and then administered to mice by
intramuscular injection in both side quadriceps with 50μlo f
the preparations at each side. For immunization with both
DNA and VLP vaccines at separate sites, 50μgD N Ao r5 0μg
VLPs were each dissolved in 50μl PBS and administered to
mice by intramuscular injection in separate side quadriceps
respectively. Mouse blood samples were collected by retro-
orbital bleeding at 14 days after each immunization, heat-
inactivated, and stored at −80◦C until analysis. All mice
received a boosting immunization at 4 weeks after priming
following the same procedure.
2.3. Flow Cytometry Analysis of CD8 T Cell Responses. Anal-
ysis of cellular immune responses by intracellular cytokine
staining and ﬂow cytometry was carried out as described
previously [29, 30]. Immunized mice were sacriﬁced two
weeks after the second immunization and mouse splenocytes
were prepared with lysis of red blood cells with ammonium
chloride and washed twice with RPMI 1640. The cells
were resuspended in complete culture medium (RPMI 1640
plus 10% fetal calf serum, 50μM beta-mercaptoethanol,
and antibiotics mix) and the cell viability was determined
by trypan blue exclusion. Cells (106)w e r ec u l t u r e di n
the presence of brefeldin A (Sigma, 10μg/mL), with a
stimulating peptide corresponding to a CTL epitope of
the HIV89.6 Env protein (IGPGRARYAR, 10μg/mL) or an
irrelevant peptide corresponding to a segment in the HIV
Gag protein (AMQMLKETI, negative control) for 6 hours.
After stimulation with peptide, the cells were washed twice
with PBS containing 3% fetal calf serum and then stained
with FITC-conjugated rat anti-CD8 and PerCP-conjugated
rat anti-CD4 antibodies (Pharmingen). Cells were then ﬁxed
and permeabilized with cytoﬁx buﬀers (Caltag) and thenJournal of Biomedicine and Biotechnology 3
stained for intracellular IFNγ using APC conjugated rat anti-
IFNγ antibody (Pharmingen). Flow cytometry analysis was
performed on a BD FACSCalibre with CELLQuest software.
2.4. ELISA. ELISA plates were coated with puriﬁed HIV-1
89.6gp120-Histag (prepared by Nicald aﬃnity puriﬁcation
using a Qiagen kit, at 2μg/mL in borate-buﬀered saline,
pH 8.5, 100μlp e rw e l l )a t4 ◦Co v e r n i g h ta n db l o c k e d
with PBS-T-BSA (phosphate-buﬀered saline, 0.1% tween-
20, 3% bovine serum album) for 3 hours at 37◦C. Serial
dilutions of mouse serum were then added to each well
in triplicate and incubated at 37◦Cf o r3h o u r s .H R P -
conjugated secondary antibody (Sigma) against mouse IgG,
I g G 1 ,o rI g G 2 aw a sa d d e df o r2h o u r sa t3 7 ◦C. After a
ﬁnal wash, ABTS (2,2 -azino-bis(3-ethybenz-thiazoline-6-
sulfonic acid), Sigma) dissolved in citrate phosphate buﬀer
(3mg ABTS in 10mL CPB, pH 4.2, plus 10μlH 2O2)w a s
added at 100μl/well for developing color and read by an
ELISA reader at 405nm. A standard curve for absorbance
and the amount of mouse antibody absorbed to the well
were obtained by coating ELISA plates with serial 2-fold
dilutions of puriﬁed mouse antibodies followed by addition
of HRP-conjugated secondary antibody and development
of color. Data were analyzed by a Microsoft Excel program
and presented as the equivalent amount of Env-binding
antibodies in mouse sera (ng/mL) and statistical analysis was
carried out using Student t-test.
2.5. Sedimentation Assay. To determine whether the DNA
and VLPs bind to each other in the DNA and VLP mixture,
we carried out a sedimentation study. The HIV Env-DNA
(50μg) and DNA and VLP mixture (50μgD N Ap l u s5 0μg
VLP) were loaded onto a two-layer sucrose cushion, with
500μl 30% sucrose at bottom and 2mL 20% sucrose above,
followedbycentrifugationat30,000RPMfor30minutesina
BeckmannSW55Tirotor.Todeterminewhethertheintegrity
of VLPs is necessary for binding to DNA molecules, we also
included a control sample in which VLPs (50μg) were lysed
by 1% Triton X-100 prior to mixing with the HIV Env-DNA
(50μg). VLPs (50μg) only were also included as a negative
control. After centrifugation, top layers were removed from
the tube and the concentration of DNA molecules in the
30% sucrose cushion was determined by UV spectrometry
at OD260. The relative amount and mobility of DNA in the
30% sucrose cushion was also examined by electrophoresis
in an agarose gel.
2.6. Bone Marrow-Derived Dendritic Cell (BMDC) Prepara-
tion and Stimulation. Mouse BMDCs were prepared follow-
ing procedures as reported by Lutz et al. in their studies
[31]. Brieﬂy, femurs were obtained from sacriﬁced mice and
the marrows were ﬂushed out with FACS medium and then
ﬁltered through a cell strainer. After lysis of red blood cells,
bone marrow leukocytes were resuspended in FACS medium
and cell numbers were counted by trypan blue staining. The
leukocytes were then seeded in 100mm bacteriological petri
dishes at 2×106 per dish in 10mL FACS medium containing
20ng/mL recombinant mouse GM-CSF. On day 3, another
10mL FACS medium containing 20ng/mL recombinant
mouse GM-CSFwasadded to eachdish. On day 6, halfof the
culture supernatant was collected, centrifuged, and the cell
pellet resuspended in 10mL fresh FACS medium containing
20ng/mLrecombinantmouseGM-CSFandthenaddedback
into the original dish. Analysis by ﬂow cytometry shows
that BMDCs prepared by this method are over 70% CD11c
positive. On day 7 of culture, 105 BMDCs were added to each
well in a 96-well plate and stimulated in vitro with HIV Env-
DNA (50μg/mL), SHIV 89.6 VLPs (10μg/mL), a mixture
of DNA (50μg/mL), and VLPs (10μg/mL), as well as with
LPS (10ng/mL, positive control) or mock-treated media
(negative control) in triplicates. In parallel, the samples were
also heated at 100
◦C for 30 minutes before being added to
DCs in the stimulation assay. Supernatants were harvested
after 24 hours of incubation at 37◦Ci n5 % C O 2,a n d
cytokine levels in cell supernatants were measured by ELISA
in duplicates using commercially available kits (eBioscience)
for IL-6, IL-12, as well as TNF-alpha according to the
manufacturer’sinstruction.FordetectionofCD80andCD86
surface expression, BMDCs were harvested after stimulation
by DNA or VLP vaccines as described above and the cells
were washed twice with PBS containing 3% fetal calf serum.
Afterwash,thecellswerestainedwithPEconjugatedratanti-
CD11c and APC conjugated rat anti-CD80 (or anti-CD86)
antibodies (Pharmingen). Cells were then ﬁxed with cytoﬁx
buﬀers (Caltag) and then analyzed by ﬂow cytometry on a
BD FACSCalibre with CELLQuest software.
3. Results
3.1. HIV Env-DNA and VLP Vaccines Exhibit Diﬀerent Abili-
ties to Induce CD8 T Cell and Antibody Responses. Construc-
tion and characterization of the HIV 89.6 Env718Tr/Y710S
DNA vaccine (designated as the Env-DNA in this study)
has been described previously [30]. SHIV 89.6 VLPs were
produced by coinfection of Sf9 insect cells with recombinant
baculoviruses expressing the HIV 89.6 Env and SIVmac239
Gag proteins, respectively. As shown in Figure 1(a),b o t h
HIV 89.6 Env and SIV Gag proteins were detected in SHIV
89.6 VLPs by Western blot. Examination of puriﬁed VLPs by
electron microscopy showed that they exhibit a uniformed
spherical morphology that is about 150nm in diameter and
similar in size to HIV virions (Figure 1(b)). The amount
of HIV Env proteins in SHIV 89.6 VLP preparations was
further determined by a sandwich ELISA using puriﬁed
HIV Env gp120 as a standard and the results showed that
there is about 100–130ng HIV Env proteins in 5μg of three
diﬀerent SHIV 89.6 VLP preparations (Figure 1(c)). After
production and characterization, the SHIV 89.6 VLPs were
used in immunization studies in comparison with the HIV
Env-DNA vaccine as outlined in Figure 2.T h ep l a s m i dD N A
vector pCAGGS and SIV Gag-VLPs that were produced by
infection of Sf9 insect cells with recombinant baculoviruses
expressing the SIVmac239 Gag protein were used as control
DNA and VLPs, respectively, in the immunization studies.
As shown in Figure 3, immunization with the Env-
DNA vaccine alone (Group 2) induced signiﬁcant levels
of CD8 T cell responses against the HIV Env with an4 Journal of Biomedicine and Biotechnology
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Figure 1: Characterization of SHIV 89.6VLPs. SHIV 89.6 VLPs were produced by coinfection of Sf9 cells with rBVs expressing HIV 89.6
Env and SIVmac239 Gag proteins at the MOI (multiplicity of infection) of 5 and 2, respectively, and puriﬁed as described in Section 2.S I V
Gag VLPs were produced by infection of Sf9 cells with rBV expressing SIVmac239 Gag proteins and puriﬁed similarly. (a) Characterization of
SHIV 89.6 VLPs by Western blot. 5μg total proteins were taken from each VLP preparation and analyzed by SDS-PAGE followed by Western
blot using rabbit-anti-gp120 antibody for detection of HIV Env proteins and monkey-anti-SIV fordetection of the SIV Gag proteins. Lanes
1, SHIV 89.6 VLP; 2, SIV Gag-only VLP. (b) Comparison of HIV 89.6 Env amount in VLP preparations by a quantitative ELISA. The amount
of HIV Env proteins in SHIV 89.6 VLP preparations was determined by a sandwich ELISA. ELISA plates were coated with a sheep-anti-
gp120 antibody as the capture antibody, followed by addition of serial 2-fold dilutions of SHIV 89.6 VLPs lysed by 1% Triton X-100. The
amount of HIV Env bound to the plate was then detected by sera from HIV-infected patients as the detecting antibody, followed by addition
of HRP-conjugated Goat-antihuman antibody and development of color. Lysed SIVmac239 Gag VLPs were used as controls. A standard
curve for the amount of HIV Env was obtained by adding puriﬁed HIV 89.6 Gp120 mixed with SIVmac239 Gag VLP lysed by 1% Triton
X-100 to the sheep-anti-gp120 antibody-coated ELISA plate. The amount of HIV Env proteins was then calculated based on the obtained
standard curve and then expressed as nanograms (ng) of HIV Env in 1μg VLP preparation. VLP1, VLP2, and VLP3 represent SHIV 89.6
VLPsproducedfromthreediﬀerentbatchesandGag-VLPrepresentsthecontrolSIVmac239GagonlyVLPpreparation.(c) Negativestaining
and EM examination of SHIV 89.6 VLPs. Puriﬁed SHIV 89.6 VLPs were stained with 1% uranyl acetate followed by examination under a
transmission electron microscope.
average of about 0.8% total CD8 T cells stimulated to
produce interferon-gamma by a peptide corresponding to
a dominant epitope in the HIV Env protein. In contrast,
no signiﬁcant level of CD8 T cell response against the
HIV Env was induced by immunization with SHIV 89.6
VLPs alone (Group 3) compared to the control group that
was immunized with a mixture of plasmid DNA vector
pCAGGS and SIV Gag-VLPs (Group 1). On the other hand,
immunization with SHIV 89.6 VLPs induced higher levels
of antibody responses against the HIV Env gp120, which
is almost twofold higher on average compared to the HIV
Env-DNA vaccine (Figure 4(a)). We further compared the
levels of IgG1 and IgG2a antibody subtypes against the HIV
Env gp120 induced by the HIV Env-DNA and VLP vaccines.
As shown in Figures 4(b) and 4(c), immunization with the
HIV Env-DNA and SHIV 89.6 VLPs induced similar levelsJournal of Biomedicine and Biotechnology 5
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Figure 2: Schematic diagram of immunization study design. Six groups of mice (groups of 6) were immunized with diﬀerent vaccine
preparations as indicated. Group 1: a mixture of 50μg DNA vector pCAGGS and 50μg SIV Gag-VLPs; Group 2: 50μg HIV Env-DNA;
Group 3: 50μg SHIV 89.6 VLPs; Group 4: a mixture of 50μg HIV Env-DNA and 50μg SHIV 89.6 VLPs; Group 5: simultaneous injection
with 50μg HIV Env-DNA and 50μg SHIV 89.6 VLPs at separate sites; Group 6: a mixture of 50μgp C A G G SD N Av e c t o ra n d5 0μgS H I V
89.6 VLPs; Group 7: a mixture of 50μg HIV Env-DNA and 50μg SIV Gag-VLPs. Mice were immunized twice by intramuscular injections
at weeks 0 and 4, and sacriﬁced at week 6 (two weeks after the second immunization) to collect blood samples and prepare splenocytes for
analysis of immune responses.
of IgG1 antibodies against the HIV Env gp120. However,
the level of IgG2a antibodies induced by SHIV 89.6 VLPs
was signiﬁcantly higher than that induced by the Env DNA
vaccine. Taken together, these results show that the HIV Env-
DNA vaccine is more potent in eliciting CD8 T cell responses
whereas the SHIV 89.6 VLPs is more eﬀective in eliciting
antibody responses against the HIV Env.
3.2. Immunization with a Mixture of the HIV Env-DNA
and VLP Vaccines Induces Enhanced CD8 T Cell Responses.
Comparison of immune responses induced by HIV Env-
DNA and VLP vaccines showed that these two diﬀerent
vaccine platforms exhibit diﬀerent abilities in eliciting CD8
T cell and antibody responses. We therefore further inves-
tigated whether a combination of these two vaccines may
complement each other. As outlined in Figure 2,m i c ei n
Group 4 were immunized with a mixture of HIV Env-
DNA and VLP vaccines. In addition, we also included three
additional groups that were immunized by simultaneous
injection of the HIV Env-DNA vaccine and SHIV 89.6 VLPs
at separate sites (Group 5), by a mixture of SHIV 89.6
VLPs and the DNA vector pCAGGS (Group 6), and by a
mixture of the HIV Env-DNA vaccine and the control SIV
Gag-only VLPs (Group 7), respectively, for comparison. As
shown in Figure 3, immunization with a mixture of HIV
Env-DNA and VLP vaccines (Group 4) induced an average
of about 2% total CD8 T cells against the Env, more than
twofold higher than the level induced in Group 2 mice
that were immunized by the HIV Env-DNA vaccine alone
(P<. 05). On the other hand, immunization by separate
injections of the HIV Env-DNA and SHIV 89.6 VLPs (Group
5)inducedanaverageofabout0.9%totalCD8Tcellsagainst
the HIV Env, similar to the level induced by immunization
with the HIV Env-DNA vaccine alone (Group 2). Moreover,
immunization with a mixture of the HIV Env-DNA vaccine
and control SIV Gag-VLPs (Group 7) induced an average
of about 1.6% total CD8 T cells against the HIV Env that
is also signiﬁcantly higher (P<. 05) compared to the levels
induced by immunization with the HIV Env-DNA vaccine
alone (Group 2) or by separate injections of HIV Env-DNA
and SHIV 89.6 VLPs (Group 5). In contrast, no signiﬁcant
CD8 T cell response was induced by immunization with a
mixture of SHIV 89.6 VLPs and the DNA vector pCAGGS
(Group 6) similar as observed for mice immunized with
SHIV 89.6 VLPs alone (Group 3), further demonstrating the
weakness of VLPs for eliciting CD8 T cell responses. These
results indicate that VLPs may exert an adjuvant activity and
augment induction of CD8 T cell responses by the HIV Env-
DNA vaccine. Moreover, administering the HIV Env-DNA
and VLPs in a mixture is necessary for eliciting enhanced
CD8 T cell responses.
3.3. Induction of Higher Levels of Antibody Responses Does Not
Require Mixing of the HIV Env DNA and VLP Vaccines during
Immunization. Analysis of antibody responses revealed a
diﬀerent outcome compared to the CD8 T cell responses.
As shown in Figure 4, immunization with the Env-DNA and
SHIV 89.6 VLP mixture (Group 4) induced higher levels
of antibody responses on average than immunization with
either the HIV Env-DNA (Group 2) or the SHIV 89.6 VLP
vaccine(Group3)alone.However,statisticalanalysisshowed
that the antibody response induced by the vaccine mixture
(Group 4) is only signiﬁcantly higher than the antibody
responses induced by the HIV Env-DNA vaccine (Group 2).
Further, while immunization by separate injections of the
HIV Env-DNA and SHIV 89.6 VLPs (Group 5) did not aug-
ment induction of CD8 T cell responses, it induced higher
levels of antibody responses against the HIV Env compared
to immunization with the HIV Env-DNA vaccine alone
(Group 2), similar to those induced by immunization with6 Journal of Biomedicine and Biotechnology
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Figure 3: Enhanced CD8 T cell responses by immunization with a mixture of HIV Env-DNA and SHIV 89.6 VLPs but not by simultaneous
injection at separate sites. Groups of mice (6 per group) were immunized by intramuscular injection at weeks 0 and 4 with diﬀerent vaccine
preparations as shown in Figure 2. Two weeks after the second immunization, mouse splenocytes were prepared and stimulated by the
peptide IGPGRAFYAR corresponding to the dominant CD8 epitope in the HIV Env for Balb/c mice. The percentages of IFNγ-producing
CD8 T cells were analyzed by intracellular-cytokine staining and ﬂow cytometry. (a) Representative results of FACS analysis for IFNγ-
producing CD8 T cells from each immunization group stimulated with the peptide IGPGRAFYAR. Numbers in lower-right boxes represent
percentages of IFNγ staining positive CD8 T cells. Background levels of IFNγ-producing CD8 T cells similar to Group 1 were obtained for
all samples stimulated with an irrelevant peptide AMQMLKETI (data not shown). (b) Percentages of IFNγ staining positive CD8 T cells
for each immunization group after stimulation with the peptide IGPGRAFYAR. Error bars represent standard deviations for each group.
∗ indicates the groups with signiﬁcantly higher levels of CD8 T cell responses than Group 2 that received the HIV Env-DNA vaccine only
(P<. 05).
the mixture of HIV Env-DNA and VLP vaccines (comparing
Group 4 and Group 5). On the other hand, while immuniza-
tion with a mixture of the HIV Env-DNA vaccine and SIV
Gag-VLPs induced enhanced CD8 T cell responses, it did not
augment induction of antibody responses against the HIV
Env. In fact, the average level of antibody response induced
by immunization with a mixture of the HIV Env-DNA
vaccineandSIVGag-VLPsislowercomparedtothatinduced
by immunization with the HIV Env-DNA vaccine alone for
both IgG1 and IgG2a antibodies (comparing Group 7 with
Group 2). Moreover, the antibody response against the HIV
Env induced by immunization with a mixture of SHIV 89.6
VLPs and the control DNA vector pCAGGS is similar to that
induced by immunization with SHIV 89.6 VLPs alone (com-
pare Group 3 and Group 6). Taken together, these results
indicatethatincontrasttoinductionofCD8Tcellresponses,Journal of Biomedicine and Biotechnology 7
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Figure 4: Comparison of antibody responses induced by immu-
nization with the HIV Env-DNA and SHIV 89.6 VLP vaccines in
diﬀerent combinations. Mice were immunized by diﬀerent vaccine
preparations as described in Figure 2. Sera were collected at 2 weeks
after the second immunization and analyzed for antibodies speciﬁc
for HIV 89.6 gp120 by ELISA. The levels of antibody responses
are expressed as the quantity (ng) of antibodies binding to HIV
89.6 gp120 in 1mL sera from each mouse. (a) Total IgG antibodies
againstgp120.(b)IgG1subtypeantibodiesagainstgp120.(c)IgG2a
subtype antibodies against gp120. Error bars indicate the standard
deviations for each immunization group. ∗ indicates the groups
with signiﬁcantly higher levels of antibody responses than Group
2 that received the HIV Env-DNA vaccine only (P<. 05).
the HIV Env-DNA and VLP vaccines do not exert an adju-
vant activity to each other for eliciting antibody responses.
Of note, while both SHIV 89.6 VLPs and HIV Env-DNA
vaccines induced similar levels of IgG1 antibody responses,
immunization with VLPs induced signiﬁcantly higher levels
of IgG2a antibodies that are over 4-fold higher compared to
the HIV Env-DNA vaccine (P<. 05). Moreover, this is sim-
ilarly observed for all groups that received SHIV 89.6 VLPs
in immunization (Groups 3, 4, 5, and 6) versus those that
received HIV Env-DNA but no SHIV 89.6 VLPs in immu-
nization(Groups2and7).Theseresultsdemonstratethatthe
proﬁles of the antibody response induced by the HIV Env-
DNA and VLP vaccines are diﬀerent and the IgG2a antibod-
ies were primarily induced by VLPs in immunization with a
mixture of HIV Env-DNA and SHIV 89.6 VLP vaccines.
3.4. VLPs Bind to DNA Molecules in the DNA and VLP Mix-
ture and Exhibit Dendritic Cell- (DC-) Stimulating Activities.
The results from above studies showed that VLPs augmented
induction of CD8 T cell responses by the HIV Env-DNA
vaccine and the adjuvant eﬀect was only observed when
VLPs and HIV Env-DNA are given as a mixture during
immunization. To delineate the underlying mechanism, we
ﬁrst investigated whether DNA molecules bind to VLPs in
the mixture by using a sedimentation assay. The HIV Env-
DNA,SHIV89.6VLP,ortheirmixturewasoverlaidontopof
a 30% sucrose cushion, and after centrifugation, the relative
amount of DNA in the bottom 30% sucrose cushion was
examined by electrophoresis in an agarose gel. To determine
whether the integrity of VLPs aﬀects binding with DNA
molecules, we also included a mixture of HIV Env-DNA
and lysed-VLPs for comparison. As shown in Figure 5(a), the
amount of DNA detected in the sample containing the DNA
and VLP mixture is much higher compared to those detected
in samples containing DNA only or DNA mixed with lysed
VLPs. Further, the DNA molecules in the sample containing
the DNA and VLP mixture also exhibited a slower mobility,
which may result from the formation of aggregates through
binding to VLPs. These results indicate that DNA and VLPs
are bound to each other in the mixture and the binding is
dependent on the integrity of VLPs.
PreviousstudieshaveshownthatSHIV89.6VLPsexhibit
DC-stimulating activities [32]. We thus further investigated
whether SHIV 89.6 VLPs stimulate cytokine secretion by
DCs when mixed with DNA molecules. As shown in
Figure 5(b), incubating DCs with SHIV 89.6 VLPs or a
mixture of HIV Env-DNA and SHIV 89.6 VLPs eﬀectively
stimulated secretion of cytokines IL-6, IL-12, as well as
TNF-alpha to similar levels as incubating DCs with bacteria
LPS. On the other hand, incubating DCs with HIV Env-
DNA molecules only did not stimulate signiﬁcant levels
of cytokine secretion as compared to unstimulated DCs.
The stimulation of DCs by SHIV 89.6 VLPs is not due to
contamination of bacteria endotoxin as boiled-SHIV 89.6
VLPs or HIV Env-DNA mixed with boiled-SHIV 89.6 VLPs
did not stimulate cytokine secretion. In contrast, boiling
does not aﬀect the ability of LPS to stimulate cytokine
secretion by DCs. We further determined surface expression
of costimulatory molecules CD80 and CD86 on DCs after8 Journal of Biomedicine and Biotechnology
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Figure 5: (a) DNA molecules bind to VLPs in the DNA/VLP mixture. HIV 89.6 Env-DNA, SHIV 89.6 VLPs, or their mixtures were loaded
onto a two-layer sucrose cushion, with 500μl 30% sucrose at bottom and 2mL 20% sucrose above, followed by ultracentrifugation. After
centrifugation, 10μl from the 30% cusion of each sample was loaded onto a 1% agarose gel, and after electrophoresis, the gel was stained
with Ethidium Bromide followed by destaining and then visualization of DNA by UV light. Marker: DNA molecular weight marker (lambda
DNA Hind III digest); VLP: 50μg SHIV 89.6 VLPs; DNA: 50μg HIV Env-DNA; DNA/VLP: 50μg HIV Env-DNA mixed with 50μgS H I V :
89.6 VLPs; DNA/VLP (lysed): 50μg HIV Env-DNA mixed with 50μg SHIV 89.6 VLPs that were lysed with 1% Triton X-100. (b) SHIV 89.6
VLPs stimulate cytokine secretion by BMDCs. BMDCs were prepared as described in Section 2 and incubated with diﬀerent stimulants in
triplicates. DCs incubated with culture medium only were used as negative controls and DCs incubated with LPS (10ng/mL) were used as
positive controls. To ensure that stimulation of DC by DNA or VLPs is not due to contamination of endotoxin, the DCs were also incubated
withthesamestimulantsthathavebeenheat-treatedat100◦Cfor30minutes.Cell-freesupernatantswereharvested24hoursafterincubation
at 37◦Ci n5 %C O 2 and assayed for the levels (pg/mL) of IL-6, IL-12, and TNF-alpha by ELISA. Error bars represent standard deviations
and the results shown represent typical results obtained from two diﬀerent stimulation experiments. Medium, cell culture medium (negative
control): LPS, 10ng/mL (positive control); DNA: HIV Env-DNA (50μg/mL); VLP: SHIV 89.6 VLPs (10μg/mL); DNA-VLP: a mixture of
HIV Env-DNA (50μg/mL) and SHIV 89.6 VLPs (10μg/mL). (c) Maturation of BMDCs after stimulation by SHIV 89.6 VLP vaccines. BMDCs
were incubated with diﬀerent stimulants as described above. After stimulation, the BMDCs were stained for surface expression of CD11c,
CD80, and CD86 and then analyzed by ﬂow cytometry. The results are presented as histograms for CD80 (upper panel) and CD86 (lower
panel) for CD11c positive cells. Medium: cell culture medium (negative control); LPS: 10ng/mL (positive control); DNA: HIV Env-DNA
(50μg/mL); VLP: SHIV 89.6 VLPs (10μg/mL); DNA-VLP: a mixture of HIV Env-DNA (50μg/mL) and SHIV 89.6 VLPs (10μg/mL).Journal of Biomedicine and Biotechnology 9
stimulation. As shown in Figure 5(c), stimulation of DCs by
VLPs or the DNA-VLP mixture signiﬁcantly increased the
surface expression of CD80 and CD86 that is comparable
to stimulation by LPS. In contrast, incubation of DCs with
DNAvaccinealonedidnotinduceupregulationofCD80and
CD86 surface expression similar to the use of medium alone.
These results show that the VLPs are highly potent in DC-
stimulation compared to DNA molecules, and this property
of VLPs may also be responsible for their adjuvant activity
to augment induction of CD8 T cell responses by the HIV
E n v - D N Av a c c i n ew h e ng i v e na sam i x t u r e .
4. Discussion
The advancement in molecular biology and biomedical
research has led to the development of new vaccine strategies
against virus infection. Among these are DNA and VLP
vaccines that both have attracted great interest for HIV
vaccine development [33]. Both DNA and VLP vaccines
share the ability to be administered repetitively for boosting
induction of immune responses without the concern for
preexisting or induced antivector immune responses. How-
ever,informationondirectcomparisonofthesetwodiﬀerent
vaccine platforms for inducing antibody and CD8 T cell
responses is still lacking. In this study, we evaluated immune
responses induced by the HIV Env-DNA and SHIV 89.6 VLP
vaccines for comparison and investigated the eﬀectiveness of
their combination for inducing both antibody and CD8 T
cell responses.
The results from this study showed that immunization
with the HIV Env-DNA vaccine induced signiﬁcant levels of
CD8 T cell responses, similar as observed in our previous
studies [30]. The potency of DNA vaccines to induce
CD8 T cell responses is probably due to direct in vivo
antigen synthesis after DNA immunization, which are more
eﬃciently presented to the MHC I antigen presentation
pathway for eliciting CD8 T cell responses [14]. In contrast,
immunization with SHIV 89.6 VLPs induced minimal to
undetectable levels of CD8 T cell responses against the HIV
Env, indicating that the VLPs are relatively poor inducers of
CD8 T cell responses similar as inactivated virus vaccines as
well as other protein-based vaccines [2]. Of note, previous
studies have shown the induction of CTL responses against
the HIV Env by HIV or SHIV VLPs [24, 25, 32]. However,
the immune response induced by VLPs was not compared
with other vaccine platforms such as DNA vaccines in those
studies and the CTL responses were assessed by assay for
cytolytic activity of T cells after in vitro stimulation. Thus,
it is possible that VLPs can elicit low levels of CD8 T cell
responses that become detectable after in vitro stimulation
as shown in early studies [24, 25, 32]. On the other hand, the
CD8 T cell responses were investigated in this study by direct
ex vivo stimulation with a peptide corresponding to the
dominant CD8 epitope in the HIV Env. Moreover, previous
studies in nonhuman primates have shown that DNA
vaccines are more eﬀective than VLPs for induction of T cell
responses against the HIV Gag protein [34]. Taken together,
these results show that the HIV DNA vaccines are more
eﬀective than the VLPs for eliciting CD8 T cell responses.
On the other hand, SHIV 89.6 VLPs were found to
induce higher levels of antibody responses compared to
the HIV Env-DNA vaccine. Interestingly, further analysis
of antibody responses showed that the proﬁles of antibody
responses induced by the HIV Env DNA vaccines and VLPs
are diﬀerent. While both SHIV 89.6 VLPs and the the HIV
Env-DNA vaccine induced similar levels of IgG1 antibody
responses, immunization with VLPs induced signiﬁcantly
higher levels of IgG2a antibodies that are over 4-fold higher
compared to the HIV Env-DNA vaccine. Moreover, this is
similarly observed for all groups that received SHIV 89.6
VLPs in immunization (Groups 3, 4, 5, and 6) versus those
that received HIV Env-DNA but no SHIV 89.6 VLPs in
immunization (Groups 2 and 7), indicating that the IgG2a
antibodies are primarily induced by immunization with
SHIV 89.6 VLPs. The underlying mechanism for antibody
subtype switch is still not clear and evidence suggests
t h a tan u m b e ro ff a c t o r ss u c ha sa n t i g e nf o r m sa sw e l l
as immunization routes may aﬀect the levels of IgG2a
antibodies [35, 36]. It has been reported that intramuscular
immunization with plasmid DNAs expressing ovalbumin or
hen egg lysozyme induced higher levels of IgG2a antibodies
than immunization with puriﬁed soluble proteins [37]. In
addition, it has also been shown that immunization with
the secreted monomer hepatitis B virus e antigens induced
predominantly IgG1 antibodies whereas immunization with
the particulate hepatitis B virus core antigens elicited mostly
IgG2a and IgG2b antibodies [38]. Moreover, it has been
recently reported than VLPs can directly activate conven-
tional B cells and promote B cell diﬀerentiation to IgG2a
producing plasma cells [39]. Thus, it is possible that the pre-
sentation of multiple Env protein complexes on the surface
of VLPs, which are particulate antigens, is more eﬀective
in eliciting IgG2a antibody responses. The induction of
enhancedIgG2aantibodyresponsesindicatesaTh1-oriented
immune response, which has been suggested to be more
eﬀective in complement activation for lysis of virus-infected
cells [37, 40]. It will be interesting to investigate whether
the induction of Th1 type antibody responses may provide
additional beneﬁt to the control of HIV infection through
moreeﬀectivecomplementﬁxationandantibody-dependent
cell cytotoxicity (ADCC) to clear virus infected cells.
Of particular interest to vaccine development, we found
that immunization with a mixture of the HIV Env-DNA
withVLPvaccinessigniﬁcantlyaugmentedinductionofCD8
T cell responses compared to immunization with the HIV
Env-DNA vaccine alone. Further, the enhancement in CD8
T cell responses was only observed in mice immunized
with a mixture of the HIV Env-DNA vaccine with VLPs
but not in mice immunized by separate injections. These
results indicate that the VLPs in the vaccine mixture exert an
adjuvant eﬀect on the induction of CD8 T cell responses by
the HIV Env-DNA vaccine. A number of studies have shown
that using liposomes to absorb DNA vaccines enhances
induction of immune responses by increasing uptake of
DNA vaccines by host cells [41]. In this study, we found
that the DNA plasmids bind to VLPs in the DNA and VLP
mixture. Thus, the observed adjuvant activity of VLPs on
DNA vaccines may result from increased uptake of DNA10 Journal of Biomedicine and Biotechnology
vaccines in a mixture with VLPs by host cells, particularly by
antigen-presenting cells (APCs) such as dendritic cells (DCs)
that are more eﬃcient in taking up particulate antigens
[42, 43]. On the other hand, we also observed that SHIV 89.6
VLPs as well as their mixture with HIV Env-DNA potently
stimulate cytokine secretion by DCs, and such stimulation
is not observed for the HIV Env-DNA alone. Thus, it is
possible that the VLPs may also augment induction of CD8
TcellresponsesbyHIVEnv-DNAthroughstimulatingAPCs
for more eﬀective antigen presentation. In contrast to CD8
T cell responses, immunization with the mixture of HIV
Env-DNA and SHIV 89.6 VLPs induced similar levels of
antibody responses to those induced by injecting HIV Env-
DNA and SHIV 89.6 VLPs at separate sites. Further, mixing
the HIV Env-DNA vaccine with SIV Gag VLPs actually
reducedinductionofantibodyresponsesdespiteasigniﬁcant
enhancement in CD8 T cell responses. This discrepancy
suggests that the underlying mechanisms for the induction
of antibody and CD8 T cell responses by the HIV Env-
DNA vaccine are likely to be diﬀerent. It is possible that the
VLPs in the mixture may target DNA molecules to speciﬁc
cell populations that are more specialized in stimulating
CD8 T cell responses. Alternatively, it is also possible that
augmented CD8 T cell responses may kill DNA-transfected
APCs through their cytotoxic activities and thus reduce
antigen production for antibody induction. Nonetheless,
the induction of strong antibody responses by the mixture
of HIV Env-DNA and VLP vaccines indicates that the
VLPs eﬀectively compensate for the reduced ability of DNA
vaccines to elicit antibody responses in such a setting.
In summary, comparison of immune responses induced
by HIV Env-DNA and VLP vaccines showed that these
two vaccine platforms exhibit diﬀerent abilities in eliciting
antibody and CD8 T cell responses. Further, immunization
with a mixture of HIV Env-DNA and VLP vaccines is able
to induce both strong antibody and CD8 T cell responses
as compared with immunization with either vaccine alone,
indicating that this approach combines the advantages of
DNA and VLP vaccines with respect to their abilities to
induced antibody and CD8 T cell responses. Moreover, VLPs
also exert an adjuvant activity on induction of CD8 T cell
responses by DNA vaccines when given as a mixture and
such an adjuvant activity is also observed for irrelevant
control VLPs, indicating that this approach may also apply
other DNA and VLP vaccines for obtaining similar results.
The induction of both strong antibody and CD8 T cell
responses by immunization with a mixture of DNA and VLP
vaccinesmaybeappliedtothedevelopmentofmoreeﬀective
vaccine strategies against HIV or other viruses for which an
eﬀective control will require both antibody and CD8 T cell
responses.
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